FindTrial
Sign In

Anti-Mullerian Hormone (AMH) and Antral Follicle Count as Markers of Ovarian Reserve- Prospective Followup of Young Cancer Patients

Phase 1 Prospective Study of Markers of Ovarian Reserve in Young Female Cancer Patients

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00930501
Acronym
Ovrescancer
Enrollment
100
Registered
2009-06-30
Start date
2009-06-30
Completion date
2013-12-31
Last updated
2009-06-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Keywords

chemotherapy, cancer, AMH, gonadotoxicity, ovarian reserve, patients exposed to chemotherapy

Brief summary

young female cancer patients have improving chances of survival. the main risk is a chronic damage to their ovarian reserve. This may lead to future infertility.

Detailed description

our objective is to prospectively follow patients before and after their cancer treatment. this should help us learn of the gonadotoxicity of various treatments as well as be able to better consult these and future patients of the need of fertility preservation techniques.

Interventions

BIOLOGICALblood tests

time 0 is pretreatment time 3, 6 , 9, 12 months from the end of chemotherapy

Sponsors

Hadassah Medical Organization
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
5 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* all females prior and after chemotherapy

Exclusion criteria

* do not consent

Design outcomes

Primary

MeasureTime frame
Anti mullerian hormone2 years

Secondary

MeasureTime frame
inhibin b2 years
menstrual history2 years
antral follicle count2 years
FSH2 years
E2 and prog2 years

Countries

Israel

Contacts

Primary ContactAriel Revel, MD
arielr2@hadassah.org.il97226776424

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026